Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Get Free Report) was the recipient of a significant increase in short interest in February. As of February 28th, there was short interest totalling 66,700 shares, an increase of 46.6% from the February 13th total of 45,500 shares. Approximately 1.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 6,080,000 shares, the days-to-cover ratio is presently 0.0 days.
Institutional Trading of Phio Pharmaceuticals
An institutional investor recently bought a new position in Phio Pharmaceuticals stock. Virtu Financial LLC acquired a new position in Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Free Report) during the 4th quarter, according to its most recent filing with the SEC. The fund acquired 40,910 shares of the company’s stock, valued at approximately $74,000. Virtu Financial LLC owned approximately 0.59% of Phio Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 57.31% of the company’s stock.
Analysts Set New Price Targets
Separately, HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective on shares of Phio Pharmaceuticals in a research report on Wednesday, February 19th.
Phio Pharmaceuticals Stock Performance
PHIO traded down $0.04 on Friday, hitting $1.29. 144,238 shares of the company were exchanged, compared to its average volume of 7,689,282. Phio Pharmaceuticals has a fifty-two week low of $1.22 and a fifty-two week high of $9.99. The firm has a market capitalization of $8.89 million, a P/E ratio of -0.12 and a beta of 1.28. The business’s fifty day moving average is $1.98 and its 200 day moving average is $2.52.
Phio Pharmaceuticals Company Profile
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.
Featured Stories
- Five stocks we like better than Phio Pharmaceuticals
- How to Start Investing in Real Estate
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- The Role Economic Reports Play in a Successful Investment Strategy
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Stock Analyst Ratings and Canadian Analyst Ratings
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.